Myozyme becomes Lumizyme after biologics scale-up

By Nick Taylor

- Last updated on GMT

Related tags Chief executive officer

Genzyme will launch the same biologic under two different names in the US after the FDA decided the drug produced at 2000L was considerably different to the 160L version.

US Food and Drug Administration (FDA) approval is now imminent, according to Genzyme, which would draw a line under a challenging 10 months for the company’s Myozyme.

In an effort to scale up production of Myozyme Genzyme built a facility housing a 2000L bioreactor, which offered considerably more capacity than the 160L site.

However, the FDA ruled that in the process of scaling up from 160L to 2000L the product had changed sufficiently to require a new Biologics License Application (BLA).

This was because of concerns about the glycosylation of the protein, which the FDA believed had been altered to such an extent in the 2000L scale production process that the product is materially different from the previous version.

Genzyme suffered as a result of the ruling, with capacity going unused and Myozyme sales not increasing to the extent predicted. However, having got through this difficult period Genzyme believes it is well placed for the next 12 months.

Henri Termeer, Genzyme’s chairman and CEO, said: “We had an excellent year last year and exceeded our earnings expectations despite the economic environment and the challenges we faced with Myozyme​.

We delivered on our financial objectives but did not ignore our future. Genzyme is stronger today than it was a year ago, and we feel confident about our future​.”

Genzyme is also hopeful that it will gain approval for the 4000L perfusion reactors that it has built in Belgium, which will be another factor in driving Myozyme sales over the coming year.

Related news

Show more

Related products

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Understanding the hidden value of quality

Understanding the hidden value of quality

Content provided by Thermo Fisher Scientific – Production Chemicals and Services | 16-Jan-2023 | White Paper

The raw material supply is too vital to leave to chance, and quality-related supply chain activities are cornerstones to your success.

Follow us


View more